银屑病药物三期试验取得积极结果 Alumis(ALMS.US)开盘飙升超154%

Core Viewpoint - Alumis (ALMS.US) shares surged over 154% to a record high of $20.60 following the announcement of positive topline results from its phase III clinical trials ONWARD1 and ONWARD2 for envudeucitinib, a next-generation highly selective oral TYK2 inhibitor targeting moderate to severe plaque psoriasis [1] Group 1: Clinical Trial Results - Envudeucitinib achieved high statistical significance in meeting all primary and secondary endpoints in the ONWARD1 and ONWARD2 trials [1] - At week 16, envudeucitinib demonstrated superior skin clearance effects compared to placebo, with a p-value of less than 0.0001 for the primary endpoint of PASI 75 and static Physician's Global Assessment (sPGA) 0/1 [1] - On average, 74% of patients reached PASI 75 and 59% achieved sPGA 0/1, with responses deepening over time [1] Group 2: Consistency of Results - The placebo-corrected response rates for the primary endpoints remained consistent between the two trials [1]